Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bradykinin competitive antagonists for classical kinin systems.

J M Stewart, R J Vavrek

    Advances in Experimental Medicine and Biology
    |January 1, 1986
    PubMed
    Summary

    Researchers modified bradykinin (BK) to create potent antagonists. Substituting specific amino acids, like D-phenylalanine and beta-2-thienylalanine, enhanced BK

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    'Transient immediate orthostatic hypotension' is preferable to 'initial' orthostatic hypotension.

    Autonomic neuroscience : basic & clinical·2025
    Same author

    Combination Treatment with Antigen-Specific Dual-Sized Microparticle System Plus Anti-CD3 Immunotherapy Fails to Synergize to Improve Late-Stage Type 1 Diabetes Prevention in Nonobese Diabetic Mice.

    ACS biomaterials science & engineering·2020
    Same author

    Engineering immunomodulatory biomaterials for type 1 diabetes.

    Nature reviews. Materials·2020
    Same author

    First Report of Colletotrichum chlorophyti Infecting Soybean Seed in Arkansas, United States.

    Plant disease·2019
    Same author

    Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

    Investigational new drugs·2017
    Same author

    First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

    Investigational new drugs·2017

    Area of Science:

    • Pharmacology
    • Medicinal Chemistry
    • Peptide Science

    Background:

    • Bradykinin (BK) is a peptide involved in various physiological processes.
    • BK antagonists are crucial for understanding and modulating BK-mediated responses.
    • Previous research focused on modifying BK structure to achieve specific biological effects.

    Purpose of the Study:

    • To develop potent and specific bradykinin (BK) antagonists.
    • To investigate the structure-activity relationships of modified BK nonapeptides.
    • To assess the efficacy of novel BK analogs in smooth muscle and blood pressure assays.

    Main Methods:

    • Peptide synthesis involving amino acid substitutions (D-phenylalanine, beta-2-thienylalanine).
    • In vitro assays using isolated rat uterus and guinea pig ileum.
    • In vivo assays measuring rat blood pressure responses.
    • Determination of antagonist potency using pA2 values and competitive antagonism analysis.

    Main Results:

    • Substitution of D-phenylalanine at position 7 converted BK into an antagonist.
    • Inclusion of beta-2-thienylalanine at positions 5 and 8 significantly increased antagonist potency.
    • [Thi5,8,DPhe7]-BK showed pA2 values of 6.5 (rat uterus) and 6.3 (guinea pig ileum).
    • N-terminal modifications influenced uterine activity but not ileum inhibition.
    • Specific uterine inhibitors were developed with no ileum antagonism.
    • Analogs demonstrated competitive antagonism of kinin responses and selectivity over substance-P and angiotensin-II.

    Conclusions:

    • Structural modifications of bradykinin can yield potent and selective antagonists.
    • Specific amino acid substitutions, particularly at positions 5, 7, and 8, are key for antagonist activity.
    • Developed analogs offer potential therapeutic applications by selectively modulating kinin pathways.

    Related Experiment Videos